Efficacy and tolerability of creon for children in infants and toddlers with pancreatic exocrine insufficiency caused by cystic fibrosis: An open-label, single-arm, multicenter study

Pancreas

Volumn 38, Issue 6, 2009, Pages 693-699

  Colombo, Carla ^a,c,d   Fredella, Clara ^a   Russo, Maria Chiara ^a   Faelli, Nadia ^a   Motta, Valentina ^a   Valmarana, Lauretta ^a   Longo, Luigina ^b   D'Orazio, Ciro ^b  

^a Fondazione IRCCS Ospedale Policlinico   (Canada)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c Fondazione IRCCS Policlinico   (United States)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Clinical trial; Coefficient of fat absorption; Cystic fibrosis; Infants; Pancreatic enzyme replacement therapy; Pancreatic exocrine insufficiency

Indexed keywords

FECES LIPID; KREON; MICROSPHERE; PANCREAS ENZYME;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; BODY HEIGHT; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENERGY; EVALUATION; FAT INTAKE; FECES; FEMALE; FEVER; GASTROENTERITIS; HUMAN; LIPID ABSORPTION; MALABSORPTION; MALE; MULTICENTER STUDY; OPEN STUDY; PANCREAS EXOCRINE INSUFFICIENCY; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RHINITIS; RHINOPHARYNGITIS; SAMPLE; SORE THROAT; VIRUS INFECTION;

CYSTIC FIBROSIS; DIETARY FATS; EXOCRINE PANCREATIC INSUFFICIENCY; FECES; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFANT; INTESTINAL ABSORPTION; MALABSORPTION SYNDROMES; MALE; PANCRELIPASE;

EID: 68949083239     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181a85eaf     Document Type: Article

References (26)

1. Kraemer R, Rudeberg A, Hadorn B, et al. Relative underweight in cystic fibrosis and its prognostic value. Acta Pediatr Scand. 1978;67:33-37.
2. Konstan MW, Butler SM, Wohl MEB, et al. Growth and nutritional indexes in early life predict lung function in cystic fibrosis. J Pediatr. 2003;142:624-630.
3. Padman R, McColley SA, Miller DP, et al. Infant care patterns at epidemiologic study of cystic fibrosis sites that achieve superior childhood lung function. Pediatrics. 2007;119:e531-e537.
4. Beker LT, Russek-Cohen E, Fink RJ. Stature as a prognostic factor in cystic fibrosis survival. J Am Diet Assoc. 2001;101:438-442.
5. Shepherd R. Achieving genetic potential for nutrition and growth in cystic fibrosis. J Pediatr. 2002;140:393-395.
6. Ramsey BW, Farrell PM, Pencharz P. Nutritional assessment and management in cystic fibrosis. Am J Clin Nutr. 1992;55:108-116.
7. Sinaasappel M, Stern M, Littlewood J, et al. Nutrition in patients with cystic fibrosis: a European consensus. J Cyst Fibros. 2002;1:51-75.
8. Erdman SH. Nutritional imperatives in cystic fibrosis therapy. Pediatr Ann. 1999;28(2):129-136.
9. Dodge JA, Turk D. Cystic fibrosis: nutritional consequences and management. Best Pract Res Clin Gastroenterol. 2006;20:531-546.
10. Lai HC, Kosorok MR, Sondel SA, et al. Growth status in children with cystic fibrosis based on the National Cystic Fibrosis Patient Registry data: evaluation of various criteria used to identify malnutrition. J Pediatr. 1998;132:478-485.
11. Park RW, Grand RJ. Gastrointestinal manifestations of cystic fibrosis. A review. Gastroenterology. 1981;81:1143-1161.
12. Littlewood JM, Wolfe SP, Conway SP. Diagnosis and treatment of intestinal malabsorption in cystic fibrosis. Pediatr Pulmonol. 2006;41: 35-49.
13. Colombo C, Battezzati A. Growth failure in cystic fibrosis: a true need for anabolic agents? J Pediatr. 2005;146:303-305.
14. Borowitz D. Update on the evaluation of pancreatic exocrine status in cystic fibrosis. Curr Opin Pulm Med. 2005;11:524-527.
15. Giglio L, Candusso M, D'Orazio C, et al. Failure to thrive: the earliest feature of cystic fibrosis in infants diagnosed by neonatal screening. Acta Paediatr. 1997;86:1162-1165.
16. Bronstein MN, Sokol RJ, Abman SH, et al. Pancreatic insufficiency, growth and nutrition in infants identified by newborn screening as having cystic fibrosis. J Pediatr. 1992;120:533-540.
17. Walkowiak J, Sands D, Nowakowska A, et al. Early decline of pancreatic function in cystic fibrosis patients with class 1 and 2 CFTR mutations. J Pediatr Gastroenterol Nutr. 2005;40:199-201.
18. Cipolli M, Castellani C, Wilcken B, et al. Pancreatic phenotype in cystic fibrosis patients identified by mutation screening. Arch Dis Child. 2007;92(10):842-846.
19. Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2002;35:246-259.
20. Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Consensus Panel. J Pediatr. 1998;132:589-595.
21. Walkowiak J, Herzig KH, Strzkala K, et al. Fecal elastase-1 is superior to fecal chymotrypsin in the assessment of pancreatic involvement in cystic fibrosis. Pediatrics. 2002;110:e7.
22. Tanner JM, Whitehouse RH. Clinical longitudinal standard for height, weight, height velocity, weight velocity and stages for puberty. Arch Dis Child. 1976;51:170.
23. Tanner JM, Whitehouse RH, Takaishi M. Standards from birth to maturity for height, weight, height velocity and weight velocity: British children, 1965. I. Arch Dis Child. 1966;41:454-471.
24. Van de Kamer JH, Bokkel Huinink T, Weyers HA. Rapid method for the determination of fat in feces. J Biol Chem. 1949;177:347-355.
25. Jeejeebhoy KN, Ahmed S, Kozek G. Determination of fecal fats containing both medium and long chain triglycerides and fatty acids. Clin Biochem. 1970;3:157-161.
26. Murphy JL, Wootton SA, Bond JA, et al. Energy content of stools in normal healthy controls and patients with cystic fibrosis. Arch Dis Child. 1991;66:495-500.